Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Accelerated Community Oncology Research Network
- Target Recruit Count
- 8
- Registration Number
- NCT00779311
- Locations
- 🇺🇸
Hematology Oncology Centers of the Northern Rockies, Billings, Montana, United States
🇺🇸The West Clinic, Memphis, Tennessee, United States
🇺🇸Central Georgia Cancer Care, Macon, Georgia, United States
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2008-10-24
- Lead Sponsor
- Fondation Wygrajmy Zdrowie
- Target Recruit Count
- 20
- Registration Number
- NCT00772694
- Locations
- 🇵🇱
Chemotherapy Unit, Dept of Urology, Instituite of Oncology, Warsaw, Poland
Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 22
- Registration Number
- NCT00768937
- Locations
- 🇦🇹
Abteilung Gastroenterologie und Hepatologie, Medizinische Universität und AKH Wien, Vienna, Austria
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
- First Posted Date
- 2008-09-25
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00759928
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2019-03-06
- Target Recruit Count
- 11
- Registration Number
- NCT00754923
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
- Conditions
- Interventions
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00734526
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 9
- Registration Number
- NCT00727532
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Human Genome Sciences Inc., a GSK Company
- Target Recruit Count
- 23
- Registration Number
- NCT00712855
- Locations
- 🇺🇸
Cedars-Sinai Health System, Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Singapore Clinical Research Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00712790
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
🇸🇬Singapore General Hospital, Singapore, Singapore
🇸🇬National Cancer Centre, Singapore, Singapore
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT00703638
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.